COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
Taking everything into account, C43 scores 8 out of 10 in our fundamental rating. C43 was compared to 54 industry peers in the Pharmaceuticals industry. C43 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. C43 is growing strongly while it also seems undervalued. This is an interesting combination C43 also has an excellent dividend rating. These ratings could make C43 a good candidate for value and dividend and growth and quality investing.
1. Profitability
1.1 Basic Checks
- C43 had positive earnings in the past year.
- In the past year C43 had a positive cash flow from operations.
- In multiple years C43 reported negative net income over the last 5 years.
- Each year in the past 5 years C43 had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 20.60%, C43 belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 26.74%, C43 is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
- The Return On Invested Capital of C43 (21.60%) is better than 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of C43 (49.94%) is better than 98.08% of its industry peers.
- C43's Profit Margin has improved in the last couple of years.
- C43's Operating Margin of 55.81% is amongst the best of the industry. C43 outperforms 100.00% of its industry peers.
- In the last couple of years the Operating Margin of C43 has grown nicely.
- The Gross Margin of C43 (83.00%) is better than 86.54% of its industry peers.
- In the last couple of years the Gross Margin of C43 has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so C43 is creating value.
- The number of shares outstanding for C43 has been reduced compared to 1 year ago.
- Compared to 5 years ago, C43 has more shares outstanding
- The debt/assets ratio for C43 has been reduced compared to a year ago.
2.2 Solvency
- C43 has an Altman-Z score of 5.80. This indicates that C43 is financially healthy and has little risk of bankruptcy at the moment.
- C43 has a better Altman-Z score (5.80) than 90.38% of its industry peers.
- The Debt to FCF ratio of C43 is 0.01, which is an excellent value as it means it would take C43, only 0.01 years of fcf income to pay off all of its debts.
- C43 has a Debt to FCF ratio of 0.01. This is amongst the best in the industry. C43 outperforms 98.08% of its industry peers.
- A Debt/Equity ratio of 0.00 indicates that C43 is not too dependend on debt financing.
- With an excellent Debt to Equity ratio value of 0.00, C43 belongs to the best of the industry, outperforming 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
- A Current Ratio of 4.19 indicates that C43 has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 4.19, C43 belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
- A Quick Ratio of 3.91 indicates that C43 has no problem at all paying its short term obligations.
- C43's Quick ratio of 3.91 is amongst the best of the industry. C43 outperforms 96.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
- C43 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1315.29%, which is quite impressive.
- C43 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 85.20% yearly.
- Looking at the last year, C43 shows a very strong growth in Revenue. The Revenue has grown by 187.55%.
- Measured over the past years, C43 shows a very strong growth in Revenue. The Revenue has been growing by 33.68% on average per year.
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
- The Earnings Per Share is expected to grow by 29.02% on average over the next years. This is a very strong growth
- C43 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.67% yearly.
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 5.98 indicates a rather cheap valuation of C43.
- Based on the Price/Earnings ratio, C43 is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 26.94. C43 is valued rather cheaply when compared to this.
- With a Price/Forward Earnings ratio of 8.09, the valuation of C43 can be described as very reasonable.
- Based on the Price/Forward Earnings ratio, C43 is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
- C43 is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, C43 is valued cheaper than 96.15% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, C43 is valued cheaply inside the industry as 94.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
- The excellent profitability rating of C43 may justify a higher PE ratio.
- C43's earnings are expected to decrease with -27.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
- C43 has a Yearly Dividend Yield of 3.85%. Purely for dividend investing, there may be better candidates out there.
- In the last 3 months the price of C43 has falen by -28.24%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- Compared to an average industry Dividend Yield of 1.59, C43 pays a bit more dividend than its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.83, C43 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
- The dividend of C43 is nicely growing with an annual growth rate of 7.41%!
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- C43 pays out 24.09% of its income as dividend. This is a sustainable payout ratio.
- C43's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)07-23 2025-07-23
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the fundamental rating for C43 stock?
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.
What is the valuation status for C43 stock?
ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.
What is the profitability of C43 stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for C43 stock?
The Earnings per Share (EPS) of COSMO PHARMACEUTICALS NV (C43.DE) is expected to decline by -23.67% in the next year.
How sustainable is the dividend of COSMO PHARMACEUTICALS NV (C43.DE) stock?
The dividend rating of COSMO PHARMACEUTICALS NV (C43.DE) is 8 / 10 and the dividend payout ratio is 24.09%.